/Catalent%20Inc_%20HQ%20in%20New%20Jersey-by%20JHVEPhoto%20via%20Shutterstock.jpg)
Despite Catalent’s outperformance relative to the broader market over the past year, Wall Street analysts remain cautious about the stock’s prospects.
Catalent, Inc. CTLT reported first-quarter fiscal 2025 adjusted loss per share of 13 cents, flat year over year. The figure was wider than the Zacks Consensus Estimate of a loss of 11 cents per share....
Catalent is expected to release its first-quarter earnings next month, and analysts expect a triple-digit profit surge.
Shares of Catalent CTLT lost 0.9% on Oct. 23 with the rise in uncertainty related to its acquisition by Novo Holding following a report from Reuters on opposition from several large pharma companies as...
Catalent CTLT recently announced that it has entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, NJ, to Ardena. Ardena is a Contract...
For Immediate ReleaseChicago, IL – October 4, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...
Wall Street is currently riding on high expectations that the Fed will implement further cuts in the benchmark lending rate this year. In its September FOMC meeting, the central bank aggressively cut the...
Despite Catalent’s outperformance relative to the broader sector, Wall Street analysts remain cautious about the stock’s prospects.
Investors in Catalent, Inc. CTLT need to pay close attention to the stock based on moves in the options market lately. That is because the Oct 18, 2024 $20 Put had some of the highest implied volatility...